

SPECIALTY GUIDELINE MANAGEMENT

PEGASYS (peginterferon alfa-2a)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Chronic Hepatitis C
 - i. In combination therapy with other hepatitis C virus (HCV) drugs for adults with compensated liver disease. Pegasys monotherapy is indicated only if the patient has contraindication or significant intolerance to other HCV drugs.
 - ii. In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease.
2. Chronic Hepatitis B
 - i. Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation.
 - ii. Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT).

B. Compendial Uses

1. Myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera, symptomatic lower-risk myelofibrosis)
2. Systemic mastocytosis
3. Adult T-cell leukemia/lymphoma
4. Mycosis fungoides/Sezary syndrome
5. Primary cutaneous CD30+ T-cell lymphoproliferative disorders
6. Hairy cell leukemia
7. Erdheim-Chester disease
8. Chronic myeloid leukemia

All other indications are considered experimental/investigational and not medically necessary.

II. INITIAL CRITERIA FOR APPROVAL

A. Chronic hepatitis C virus (HCV) infection

Refer to the SGM of requested regimen for the specific criteria for approval and approval durations.

B. Chronic hepatitis B virus (HBV) infection (including hepatitis D virus [HDV] coinfection)

Authorization of up to 48 weeks total may be granted for treatment of chronic HBV infection, including HDV coinfection.

C. Myeloproliferative neoplasms

Authorization of 12 months may be granted for treatment of myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera, symptomatic lower-risk myelofibrosis).

D. Systemic mastocytosis

Authorization of 12 months may be granted for treatment of systemic mastocytosis.

E. Adult T-cell leukemia/lymphoma

Authorization of 12 months may be granted for treatment of adult T-cell leukemia/lymphoma.

F. Mycosis fungoides/Sezary syndrome

Authorization of 12 months may be granted for treatment of mycosis fungoides/Sezary syndrome.

G. Primary cutaneous CD30+ T-cell lymphoproliferative disorders

Authorization of 12 months may be granted for the treatment of primary cutaneous CD30+ T-cell lymphoproliferative disorders.

H. Hairy cell leukemia

Authorization of 12 months may be granted for treatment of hairy cell leukemia.

I. Erdheim-Chester disease

Authorization of 12 months may be granted for treatment of Erdheim-Chester disease.

J. Chronic myeloid leukemia

Authorization of 12 months may be granted for treatment of chronic myeloid leukemia in pregnancy.

III. CONTINUATION OF THERAPY

A. Chronic HCV infection and chronic HBV infection (including HDV coinfection)

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

B. Myeloproliferative neoplasm

Authorization of 12 months may be granted if the member is experiencing benefit from therapy as evidenced by improvement in symptoms and/or disease markers (e.g., morphological response, reduction or stabilization in spleen size, improvement of thrombocytosis/leukocytosis).

C. Systemic mastocytosis

Authorization of 12 months may be granted if the member is experiencing benefit from therapy as evidenced by improvement in symptoms and/or disease markers (e.g., reduction in serum and urine metabolites of mast cell activation, improvement in cutaneous lesions, skeletal disease, bone marrow mast cell burden).

D. All other indications

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for all other indications in Section II, not previously listed, when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

IV. REFERENCES

1. Pegasys [package insert]. South San Francisco, CA: Genentech, Inc; March 2021.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed March 12, 2024.
3. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.
4. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018;67(4):1560-1599.